Press Release: Novartis to acquire Xiidra(R), -2-

Aktien in diesem Artikel

Novartis AG

81,80 EUR
0,58%

• Charts
• News
• Analysen

Novartis AG

81,80 EUR 0,58%

• Charts
• News
• Analysen

Kaufen

Verkaufen

Alle anzeigen

globally and we are finding innovative ways to expand access to our

latest treatments. About 105 000 people of more than 140 nationalities

work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

http://twitter.com/novartis

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

References

[1] Novartis International AG. (2018). Novartis Q4 and FY 2018

Condensed Financial Report - Supplementary Data. Retrieved from:

https://www.novartis.com/sites/www.novartis.com/files/2019-01-financial-report-en.pdf.

[2] FDA. Xiidra (lifitegrast ophthalmic solution). Prescribing

information. Available at:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208073s000lbl.pdf.

Accessed April 25, 2019.

[3] Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the

beaver dam offspring study: prevalence, risk factors, and health-related

quality of life. Am J Ophthalmol. 2014;157(4):799-806.

doi:10.1016/j.ajo.2013.12.023.

[4] American Optometric Association. Dry Eye. Available at:

https://www.aoa.org/patients-and-public/eye-and-vision-problems/glossary-of-eye-and-vision-conditions/dry-eye#1.

Accessed April 25, 2019.

[5] Sheppard AL, Wolffsohn JS. Digital eye strain: prevalence,

measurement and amelioration. BMJ Open Ophthalmol. 2018;3(1):e000146.

doi:10.1136/bmjophth-2018-000146.

[6] Bradley JL, Özer Stillman I, Pivneva I, et al. Dry eye

disease ranking among common reasons for seeking eye care in a large US

claims database. Clin Ophthalmol. 2019;13:225-232.

doi:10.2147/OPTH.S188314.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Amy Wolf Peter Zuest

Global Head Communications, Ophthalmology Novartis Global Media Relations

+41 61 696 58 94 (direct) +41 79 899 9812 (mobile)

+41 79 576 07 23 (mobile) peter.zuest@novartis.com

amy.wolf@novartis.com

Eric Althoff

Novartis US External Communications

+1 646 438 4335

eric.althoff@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 862 778-3275

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 862 778-3258

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2243879/885977.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

May 08, 2019 18:20 ET (22:20 GMT)